Non-Invasive Monitoring Systems Aktsia

Non-Invasive Monitoring Systems ROE

ROE (Return on Equity) ettevõttest Non-Invasive Monitoring Systems (NIMU) seisuga 16. aug 2026 on 23,44 %. Eelmisel aastal oli ROE (Return on Equity) 15,59 % — muutus 50,41% (kõrgem).

ROE

23,44 %

YoY

50,41%

Viimati uuendatud:

Aastal 2026 oli Non-Invasive Monitoring Systems omakapitali tootlus (ROE) 23,44 %, mis on 50,41% suurem võrreldes 15,59 % ROE-ga eelmisel aastal.
Access this data via the Eulerpool API

Non-Invasive Monitoring Systems Aktsiate analüüs

Mida Non-Invasive Monitoring Systems teeb? Non-Invasive Monitoring Systems Inc (NIMS) has become a major player in the field of medical diagnostics and monitoring in recent years. The company was founded in 2002 and is headquartered in Miami, Florida. Its focus is on developing and marketing innovative non-invasive technologies that enable better patient care. NIMS' business model is based on the development and marketing of products that allow for fast and accurate diagnosis of various medical conditions. These technologies can be used in various clinical areas such as intensive care, oncology, cardiology, and neurology. The company's goal is to improve patient care by making diagnostics and monitoring faster, more accurate, and more effective. NIMS has several divisions that focus on different medical applications. One of these is the gastrointestinal division, which specializes in the diagnosis and monitoring of gastrointestinal disorders. NIMS offers innovative technologies such as magnetic resonance elastography (MRE-MRI), which allows for the measurement of tissue hardness without invasive procedures. This technology is particularly used in the early detection of cancer, as it enables the detection of tissue changes at an early stage. Another important division of NIMS is cardiovascular monitoring, which aims at the early detection and monitoring of heart diseases. The company offers various non-invasive technologies for this purpose, such as wearable devices for measuring blood pressure and heart rate, or ultrasound for measuring blood flow and vascular stiffness. These technologies are intended to improve the monitoring of patients with heart diseases and to detect complications at an early stage. NIMS also offers innovative diagnostic tools for the early detection of cancer, such as the Cancer Screening Index (CSI). The CSI is a biomarker-based test that calculates the probability of developing certain types of cancer. Various factors such as family history, smoking, or age are taken into account in the calculation. The CSI aims to contribute to the early detection of cancer and thus enable better prognosis. In addition to these products, NIMS is also involved in clinical research. The company offers specialized services such as conducting clinical trials or providing expert opinions. These services are intended to promote the development of new non-invasive diagnostic and monitoring technologies and thus improve overall patient care. Overall, NIMS has become a leading company in the field of non-invasive medical diagnostics and monitoring. The company is constantly striving to advance the development of new innovative technologies to improve patient care and minimize the use of invasive procedures. With its various divisions and products, NIMS is able to cover various medical applications and thus appeal to a broad customer base. Non-Invasive Monitoring Systems on üks populaarsemaid ettevõtteid Eulpoolist.

ROE detailides

Omakapitali tootluse (ROE) dešifreerimine ettevõttes Non-Invasive Monitoring Systems

Ettevõtte Non-Invasive Monitoring Systems omakapitali tootlus (ROE) on põhinäitaja, mis hindab ettevõtte rentaablust omakapitali suhtes. ROE, mis arvutatakse netokasumi jagamisel aktsionäride omakapitaliga, illustreerib, kui tõhusalt ettevõte genereerib kasumeid aktsionäride investeeringutelt. Kõrgem ROE näitab suurenenud efektiivsust ja rentaablust.

Aasta-aasta võrdlus

Ettevõtte Non-Invasive Monitoring Systems ROE analüüs aasta-aasta võrdluses aitab jälgida rentaablustrende ja finantssooritust. ROE tõus näitab suurenevat rentaablust ja väärtuse loomist aktsionäridele, samas kui ROE vähenemine võib osutada probleemidele kasumite genereerimisel või omakapitali haldamisel.

Mõju investeeringutele

Ettevõtte Non-Invasive Monitoring Systems ROE on investorite jaoks oluline, sest see aitab hinnata ettevõtte rentaablust, efektiivsust ja investeerimisatraktiivsust. Tugev ROE näitab ettevõtte võimet muuta omakapitali investeeringud kasumiks, suurendades sellega selle atraktiivsust potentsiaalsetele ja praegustele investoritele.

ROE kõikumiste tõlgendamine

Muutused ettevõtte Non-Invasive Monitoring Systems ROEs võivad tuleneda netokasumi, omakapitali või mõlema kõikumistest. Neid kõikumisi uuritakse, et hinnata juhtkonna efektiivsust, finantsstrateegiaid ning nendega seotud riske ja võimalusi, aidates investoritel teha informeeritud otsuseid.

Sageli esitatud küsimused Non-Invasive Monitoring Systems aktsia kohta

Non-Invasive Monitoring Systems ROE (Return on Equity) on 2026. aastal 23,44 %.

ROE (Return on Equity) ettevõttest Non-Invasive Monitoring Systems muutus 15,59 % -st 23,44 % -ks, mis vastab 50,41% muutusele. Väärtus on kõrgem kui eelmisel aastal.

Eulpoolist leiate ROE (Return on Equity) Non-Invasive Monitoring Systems täieliku ajaloolise arengu alates 2006. aastast – koos aastate väärtustega, graafikutega ja üksikasjalike analüüsidega.

Hea väärtus varieerub tööstuse ja ettevõtte arenguetapi järgi. Eulpoolis saate ROE (Return on Equity) Non-Invasive Monitoring Systems võrrelda sektori konkurentidega ja tööstuse keskmisega, et hinnata selle atraktiivsust.

ROE (Return on Equity) hindamiseks on oluline võrrelda seda sama tööstuse ja sektori ettevõtetega. Eulpoolis leiate ROE (Return on Equity) jaoks otsesed tööstusesisesed võrdlused.

Access this data via the Eulerpool API

Kasumlikkus — Non-Invasive Monitoring Systems

Kõik finantsnäitajad — Non-Invasive Monitoring Systems